<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873090</url>
  </required_header>
  <id_info>
    <org_study_id>1136</org_study_id>
    <nct_id>NCT03873090</nct_id>
  </id_info>
  <brief_title>SBRT in 4 Fractions for Prostate Cancer</brief_title>
  <official_title>Phase I-II Study of High Dose SBRT in 4 Fractions for Intermediate Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicentric phase-I-II pilot feasibility study. The main objective is
      to study early and late side effects of hypofractionated accelerated RT for prostate cancer
      with FFF (Free Flattened Filter) beam. The schedule will be [ 4 x 9.5 Gy = 38 Gy ] delivered
      in 5 alternative days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2013</start_date>
  <completion_date type="Actual">May 23, 2018</completion_date>
  <primary_completion_date type="Actual">May 23, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity assessment of 4 fractions SBRT in selected intermediate risk prostate cancer patients.</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Toxicity assessment: The presence and grading (CTAE v3/ EORTC-RTOG) of adverse events will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumour response to local radiation therapy by assessing freedom from biochemical failure.</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Tumour response is evaluated on ASTRO DEFINITION of PSA relapse (+2 from Nadir of PSA).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT in 4 fraction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selected intermediate risk prostate cancer patients treated with 4 fraction SBRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>hypofractionated accelerated RT for prostate cancer with FFF (Free Flattened Filter) beam. The schedule will be [ 4 x 9.5 Gy = 38 Gy ] delivered in 5 alternative days, corresponding to an NTD2 between 95 and 119 Gy for an α/β estimate between 3 and 1.5 Gy.</description>
    <arm_group_label>SBRT in 4 fraction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≤ 85years.

          -  WHO performance status ≤ 2.

          -  PSA&gt;10 and ≤ 20 ng/ml or Gleason Score 7 or T2a-T2c.

          -  Histologically proven prostate adenocarcinoma

          -  No pathologic lymph nodes on CT/ MRI scan.

          -  No distant metastases.

          -  No previous prostate surgery other than TURP (at least 6 weeks interval before
             initiation of RT).

          -  No malignant tumours in the previous 5 years.

          -  IPSS 0-7.

          -  Combined HT according to risk factors.

          -  Informed consent.

        Exclusion Criteria:

          -  Prostate size greater than 60cc.

          -  Previous TURP less than 6 weeks before radiotherapy.

          -  Previous prostate surgery other than TURP.

          -  Diabetes *.

          -  Use of anticoagulants drugs *.

          -  Chronic inflammatory bowel disease *.

          -  Previous pelvic irradiation.

          -  Inability to obtain written informed consent.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>Head of Clinical Trial Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

